Jasper Therapeutics, Inc. (JSPR)

Market Cap	324.85M
Revenue (ttm)	n/a
Net Income (ttm)	-64.47M
Shares Out	15.06M
EPS (ttm)	-6.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,483
Open	23.21
Previous Close	23.21
Day's Range	21.46 - 23.58
52-Week Range	4.00 - 31.01
Beta	2.22
Analysts	Buy
Price Target	64.79 (+199.95%)
Earnings Date	May 10, 2024

About JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lowe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: JSPR

Analyst Forecast

According to 8 analysts, the average rating for JSPR stock is "Buy." The 12-month stock price forecast is $64.79, which is an increase of 199.95% from the latest price.

Price Target

$64.79

(199.95% upside)

Analyst Consensus: Buy